{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '143 Park Drive',
 'address2': 'Milton Park',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 15,
 'askSize': 3200,
 'averageDailyVolume10Day': 166562,
 'averageVolume': 247390,
 'averageVolume10days': 166562,
 'beta': 1.062745,
 'beta3Year': None,
 'bid': 13.33,
 'bidSize': 1400,
 'bookValue': 7.632,
 'category': None,
 'circulatingSupply': None,
 'city': 'Abingdon',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.92,
 'dayLow': 13.26,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -28.533,
 'enterpriseToRevenue': 2.584,
 'enterpriseValue': 188234128,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '44 1235 442 781',
 'fiftyDayAverage': 13.438857,
 'fiftyTwoWeekHigh': 17.77,
 'fiftyTwoWeekLow': 8.37,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 20790563,
 'forwardEps': -0.16,
 'forwardPE': -83.5,
 'fromCurrency': None,
 'fullTimeEmployees': 243,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.18030001,
 'heldPercentInstitutions': 1.01641,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/oxfordimmunotec.com',
 'longBusinessSummary': 'Oxford Immunotec Global PLC, a diagnostics company, '
                        'focuses on developing and commercializing proprietary '
                        'tests for immunology and infectious diseases in the '
                        'United States, Europe, Asia, and internationally. The '
                        'company develops its products using its T-SPOT '
                        'technology platform that measures marker-specific '
                        'cellular (T cells) responses at a single cell level '
                        'and inform the diagnosis, prognosis, and monitoring '
                        'of patients with immune-regulated conditions. It '
                        'develops and markets T-SPOT.TB test used to test for '
                        'tuberculosis; and reagents and methods to purify '
                        'white blood cells for use in immunology assays. In '
                        'addition, the company offers T-SPOT.CMV, an immune '
                        'monitoring test for cytomegalovirus (CMV) for the '
                        'quantification of effector T cells that respond to '
                        'stimulation by antigens specific for CMV, as well as '
                        'for the monitoring of CMV-seropositive responses in '
                        'transplant recipients at various time-points '
                        'post-transplantation applications. It serves '
                        'independent laboratories, hospital systems, and '
                        'public and private institutions. Oxford Immunotec '
                        'Global PLC was founded in 2002 and is headquartered '
                        'in Abingdon, the United Kingdom.',
 'longName': 'Oxford Immunotec Global PLC',
 'market': 'us_market',
 'marketCap': 346638560,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_7756191',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -5054000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.92,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 188.5,
 'phone': '44 1235 442 780',
 'previousClose': 13.8,
 'priceHint': 2,
 'priceToBook': 1.750524,
 'priceToSalesTrailing12Months': 4.7594266,
 'profitMargins': -0.08705,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.92,
 'regularMarketDayLow': 13.26,
 'regularMarketOpen': 13.92,
 'regularMarketPreviousClose': 13.8,
 'regularMarketPrice': 13.92,
 'regularMarketVolume': 228316,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 25946000,
 'sharesPercentSharesOut': 0.0212,
 'sharesShort': 551187,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 528352,
 'shortName': 'Oxford Immunotec Global PLC',
 'shortPercentOfFloat': 0.0256,
 'shortRatio': 2.93,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'OXFD',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.239,
 'twoHundredDayAverage': 12.961799,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '113112bd-c797-3285-b8e5-eb7cb7fff35a',
 'volume': 228316,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.oxfordimmunotec.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'OX14 4SE'}